Cloutier Marc, Simard Carl, Jobin Christine, Fournier Diane, Néron Sonia
Department of Biochemistry, Microbiology and Bio-Informatics, Laval University, Québec City, Québec.
1Department of Research and Development, Héma-Québec, Québec City, Québec, Canada.
Transfusion. 2016 Jul;56(7):1786-91. doi: 10.1111/trf.13633. Epub 2016 May 3.
Preparation of umbilical cord blood units (CBUs) for infusion requires a step of dilution or washing to reduce the toxicity of the dimethyl sulfoxide present in the freezing solution. However, the worldwide shortage of clinical-grade dextran 40, the most widely used cord blood dilution or washing solution, prompted us to search for an alternative solution. We elected to evaluate the performance of alternative solutions that could be used as potential replacements for the dextran 40-based solution.
Frozen CBUs were rapidly thawed and immediately diluted 1:4 in each of 10 dilution solution variants of dextran 40, Plasma-lyte, or Hespan. We compared these alternatives by assessing viability, CD34, CD45, and colony-forming units recovery postthaw.
A significantly lower CD34 and CD45 recovery was observed in all solutions without human serum albumin (HSA). All solutions with 5% HSA gave recovery, viability, and potency figures similar to the dextran 40/HSA solution.
Based on our results and considering that Plasma-lyte A (PA)/HSA is already used for the thawing of CD34 from mobilized blood, we conclude that PA/HSA could be a safe and efficient solution for the replacement of dextran 40-based dilution solutions.
制备用于输注的脐带血单位（CBU）需要进行稀释或洗涤步骤，以降低冷冻溶液中存在的二甲基亚砜的毒性。然而，临床级右旋糖酐40（全球使用最广泛的脐带血稀释或洗涤溶液）的全球短缺促使我们寻找替代溶液。我们选择评估可作为基于右旋糖酐40的溶液潜在替代品的替代溶液的性能。
将冷冻的CBU快速解冻，并立即在右旋糖酐40、Plasma-lyte或贺斯的10种稀释溶液变体中的每一种中按1:4进行稀释。我们通过评估解冻后的活力、CD34、CD45和集落形成单位回收率来比较这些替代品。
在所有不含人血清白蛋白（HSA）的溶液中，观察到CD34和CD45回收率显著降低。所有含5%HSA的溶液的回收率、活力和效力数据与右旋糖酐40/HSA溶液相似。
基于我们的结果，并考虑到Plasma-lyte A（PA）/HSA已用于从动员血液中解冻CD34，我们得出结论，PA/HSA可能是替代基于右旋糖酐40的稀释溶液的安全有效溶液。
